HiryakKKorenDE.Fostemsavir: a novel attachment inhibitor for patients with multidrug-resistant HIV-1 infection. Ann Pharmacother. 2021;55:792-797. doi:10.1177/1060028020962424
2.
Rukobio. Package insert. ViiV; 2020.
3.
LatailladeMLalezariJPKozalMAbergJAPialouxG.Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2021;7:e740-e751. doi:10.1016/S2352-3018(20)30240-X
4.
ZhangHCustodioJMWeiX, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Paper presented at: The Annual Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA.
5.
WensingAMCalvezVCeccherini-SilbersteinF, et al. 2019 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27:111-121.
